Evidence map›Paper›PMID 41783028›Full record

ArticleJAC-antimicrobial resistance2026

Trends in population structure, antimicrobial susceptibility and resistance determinants of

Izumo Kanesaka, Kohji Komori, Masahiro Morita, Kotaro Aoki, Sheeba Santhini Manoharan-Basil, Chris Kenyon, Akiko Kanayama Katsuse, Kazuhiro Tateda, Intetsu Kobayashi, Yoshikazu Ishii

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Izumo KanesakaDepartment of Infection Control and Prevention, Faculty of Nursing, Toho University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5918-2297
Kohji KomoriDivision of Collaborative Regional Infection Control, Department of Community Well-Being, Toho University School of Medicine, Tokyo, Japan.
Masahiro MoritaDepartment of Infection Control and Prevention, Faculty of Nursing, Toho University, Tokyo, Japan.
Kotaro AokiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Sheeba Santhini Manoharan-BasilSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0001-8421-5137
Chris KenyonSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-2557-8998
Akiko Kanayama KatsuseDepartment of Infection Control and Prevention, Faculty of Nursing, Toho University, Tokyo, Japan.
Kazuhiro TatedaDivision of Collaborative Regional Infection Control, Department of Community Well-Being, Toho University School of Medicine, Tokyo, Japan.
Intetsu KobayashiDepartment of Infection Control and Prevention, Faculty of Nursing, Toho University, Tokyo, Japan.
Yoshikazu IshiiCenter for the Planetary Health and Innovation Science (PHIS), The IDEC Institute, Hiroshima University, Higashi-Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The spread of antimicrobial-resistant Methods: Of 985 gonococcus isolates obtained from clinical specimens submitted by health care institutions in the Kanto region of Japan between 2017 and 2023, one isolate per patient per year was eligible, and up to 50 isolates per year were randomly selected. A total of 349 isolates were analysed. MICs were determined by the agar dilution method. Multilocus sequence typing and Results: Over this study period, 29 sequence types (STs) were identified. Only one ceftriaxone non-susceptible strain-harbouring mosaic Conclusions: Ceftriaxone remains a reliable first-line treatment option for gonorrhoea. Ongoing surveillance is essential to detect emerging fluoroquinolone-susceptible lineages that may inform future treatment strategies.

Identifiers

PMID41783028
PMCPMC12954394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.